- Drug combo slashes risk of cancer returning after surgery
- Helps patients who can’t handle strong chemo drugs
- Not yet standard care — still under review
This treatment could change outcomes for many who previously had limited options.
Imagine facing bladder cancer surgery with no way to lower the odds the cancer comes back. That’s the reality for patients who can’t handle cisplatin, a powerful chemo drug. Without it, their chance of long-term survival drops.
Now, a new approach is turning heads. A recent study shows a two-drug combo given before and after surgery may more than double the odds of staying cancer-free.
Bladder cancer is more common than many think. About 80,000 people in the U.S. are diagnosed each year. When the cancer invades the muscle layer of the bladder, it’s serious. Surgery to remove the bladder is often the next step.
But surgery alone isn’t always enough. Without chemo, cancer often returns. The problem? Roughly half of these patients can’t take cisplatin, the usual chemo, due to age, kidney issues, or other health problems.
There’s been no proven alternative — until now.
The surprising shift
For years, doctors believed that if you couldn’t handle cisplatin, you just went straight to surgery. No chemo. Higher risk of cancer coming back.
But here’s the twist: this study tested a new strategy. Instead of skipping chemo, patients got two powerful drugs — enfortumab vedotin and pembrolizumab — around the time of surgery.
These aren’t old-school chemo drugs. One targets a protein on cancer cells like a homing missile. The other wakes up the immune system to fight cancer.
Think of cancer cells like rogue machines in a factory. Enfortumab vedotin is like a delivery truck with a tracking number for one specific machine part — a protein called nectin-4 found on bladder cancer cells.
Once it finds the cell, it releases a poison inside. The cell dies.
Pembrolizumab, the second drug, acts like a brake release for the immune system. Normally, cancer hides from immune cells. This drug removes the invisibility cloak.
Together, they attack cancer from two angles — before and after surgery.
The study included 344 patients with muscle-invasive bladder cancer who couldn’t take cisplatin. They were split into two groups.
One group got the two-drug combo plus surgery. The other had surgery alone. The combo group received treatment for about a year — three cycles before surgery, then more after.
At two years, 75% of patients on the drug combo were free from cancer returning or death. Only 39% in the surgery-only group were.
That’s a huge gap. It means nearly twice as many people stayed cancer-free.
Survival rates also improved. Nearly 80% of the combo group were still alive at two years, compared to 63% in the surgery group.
And here’s a powerful sign: over half — 57% — who got the drugs had no living cancer cells found in their removed bladders. That’s called a pathological complete response. Only 9% in the surgery group reached that mark.
This doesn’t mean this treatment is available yet.
But there’s a catch.
The drugs come with side effects. Every patient in the combo group had some form of side effect. Most were manageable — like fatigue, rash, or nausea.
But about 71% had serious side effects — including nerve pain, low blood cell counts, or infections. Still, most were able to finish treatment.
Compared to surgery alone, the risks are higher — but so are the benefits.
Doctors not involved in the study say this is one of the most promising results seen in bladder cancer in years. For patients who’ve had few options, this combo could become a new standard — if confirmed in broader use.
It’s especially meaningful because it’s the first major advance for those ineligible for cisplatin in over a decade.
If you or a loved one faces bladder cancer and can’t take cisplatin, this study offers real hope. But it’s not yet approved as a standard treatment.
You can’t just ask your doctor for it today. The results are strong, but regulators still need to review them. Trials are ongoing.
Talk to your care team about whether you might qualify for similar therapies in clinical trials.
The study was large for this type of cancer, but it’s still early. Most patients were from North America and Europe. Results may vary in other groups.
Also, the follow-up time averages just over two years. We need more data to know if the benefits last five, ten, or twenty years.
Regulators are now reviewing the data. A decision could come in the next year. If approved, this combo could become a new go-to option for patients who can’t take cisplatin.
More studies are also testing this approach in earlier stages of bladder cancer — possibly sparing some patients from surgery altogether.